A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT07536308 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

80

Enrollment

NIH

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: OCU500

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)